Compound comparison
CJC-1295 with DAC and CJC-1295 without DAC (Modified GRF 1-29) are two forms of a synthetic GHRH analog distinguished by the presence or absence of a Drug Affinity Complex moiety that binds serum albumin. The DAC variant extends the half-life from minutes to days; the non-DAC variant (Mod GRF 1-29) retains a short half-life closer to endogenous GHRH. Neither form is FDA-approved. The single published human pharmacokinetic study (Teichman et al., 2006) studied the DAC form. Both are sold as research-use-only products and are subject to FDA enforcement.
| Attribute | CJC-1295 with DAC | CJC-1295 without DAC (Modified GRF 1-29) |
|---|---|---|
| Mechanism | GHRH analog with DAC moiety that binds serum albumin, extending duration of action | GHRH analog (Modified GRF 1-29) without albumin-binding moiety; stimulates endogenous GH release via pituitary GHRH receptors |
| Half-life | Approximately 8 days (albumin-bound); GH/IGF-1 elevation observed up to 6 days post-dose | Minutes (approximately 30 minutes or less); requires more frequent administration to sustain GH pulses |
| Evidence level | One published human pharmacokinetic study (Teichman et al., 2006, JCEM); no clinical outcomes trials | No published human pharmacokinetic or clinical trial data as a distinct compound; community extrapolation from DAC form data |
| Regulatory status | Not FDA-approved; ConjuChem discontinued development; listed on FDA bulk drug substances risk list | Not FDA-approved; subject to same FDA enforcement as DAC form when marketed outside research-use-only channels |
| Supplier availability | Sold by research-use-only vendors; subject to FDA warning letters and enforcement actions | Sold by research-use-only vendors; frequently marketed alongside or as an alternative to the DAC form |
CJC-1295 with DAC was developed by ConjuChem Biotechnologies using Drug Affinity Complex technology. The DAC moiety covalently binds to serum albumin in vivo, extending the compound's half-life from minutes to approximately 8 days. This was the form studied in the only published human pharmacokinetic trial (Teichman et al., 2006).
The Teichman et al. (2006) study, published in the Journal of Clinical Endocrinology & Metabolism, showed that a single dose of CJC-1295 with DAC elevated GH and IGF-1 levels in healthy subjects for up to 6 days. This is a pharmacokinetic study, not a clinical outcomes trial — it does not establish efficacy for any indication.
ConjuChem discontinued clinical development, and CJC-1295 with DAC was never submitted to the FDA for approval. It appears on the FDA's bulk drug substances risk list and is subject to enforcement when marketed outside research-use-only channels.
CJC-1295 without DAC — also referred to as Modified GRF 1-29 or Mod GRF (1-29) — is a truncated GHRH analog that retains the biologically active 1-29 amino acid sequence of growth hormone-releasing hormone but lacks the Drug Affinity Complex moiety. Without albumin binding, its half-life is measured in minutes rather than days, more closely approximating the pulsatile release pattern of endogenous GHRH.
No published human clinical trial data exists specifically for CJC-1295 without DAC as a distinct compound. The pharmacokinetic and pharmacodynamic data from the Teichman et al. (2006) study applies to the DAC form; extrapolation to the non-DAC variant is a community assumption, not an evidence-based conclusion.
Like the DAC variant, CJC-1295 without DAC is not FDA-approved for any indication and is sold in research-use-only contexts. It appears alongside the DAC form in FDA enforcement discussions about peptide products marketed online.
The primary mechanistic difference between CJC-1295 with DAC and without DAC is the presence of the albumin-binding Drug Affinity Complex, which extends the half-life from minutes to days. The only published human data (Teichman et al., 2006) applies to the DAC form; the non-DAC variant lacks compound-specific clinical evidence. Neither form is FDA-approved. Both are sold as research-use-only products and are subject to FDA enforcement. This comparison documents mechanistic and evidence-level differences; it does not recommend either form or provide treatment guidance.
Related compounds: CJC-1295 · Ipamorelin
Source records are stored in the repo and linked from this comparison.
Teichman et al. (2006) pharmacokinetic study (PMID 16569233) showing that CJC-1295 increased GH and IGF-1 levels in healthy subjects for up to 6 days after a single dose. The primary published human data for CJC-1295.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.